Latest News and Press Releases

Rapport Therapeutics to Participate in Upcoming Investor Conferences

Rapport will present two encore posters at the American Academy of Neurology Annual Mtg - data on RAP-219, which is in current Ph2a trial in focal epilepsy

Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Rapport appoints Dr. Jeffrey Sevigny as CMO, a physician-scientist with more than 15 years of translational and clinical drug development

Rapport Therapeutics will participate in fireside chats at the upcoming TD Cowen 45th Annual Health Care Conference and Stifel 2025 Virtual CNS Forum.

Rapport announced new data from its Phase 1 PET and MAD-2 trials for RAP-219 being studied as a novel precision medicine for patients with CNS disorders.

Rapport announced new data from its Phase 1 PET and MAD-2 trials for RAP-219 being studied as a novel precision medicine for patients with CNS disorders.

Rapport presents new data on the linear relationship between a seizure biomarker used in the company's RAP-219 POC trial and clinical seizures.

BOSTON and SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule...

Biotech industry leaders added to the Board of Directors, bringing deep expertise in drug discovery, neuroscience clinical development, and operational leadershipRAP-219 MAD-2 and PET trials ongoing;...